The present invention provides self-contained systems for performing an assay for determining a chemical state, the system including a stationary cartridge for performing the assay therein, at least one reagent adapted to react with a sample; and at least one reporter functionality adapted to report a reaction of the at least one reagent with said sample to report a result of the assay, wherein the at least one reagent, the sample and the at least one reporter functionality are contained within the cartridge.

Methods are disclosed for treating a subject with a tumor. These methods include administering to the subject a therapeutically effective amount of CD8.sup.+CD39.sup.+CD103.sup.+ T cells. Methods also are disclosed for isolating a nucleic acid encoding a T cell receptor (TCR) that specifically binds a tumor cell antigen. These methods include isolating CD8.sup.+CD39.sup.+CD103.sup.+ T cells from a sample from a subject with a tumor expressing the tumor cell antigen, and cloning a nucleic acid molecule encoding a TCR from the CD8.sup.+CD39.sup.+CD103.sup.+ T cells. In addition, methods are disclosed for expanding CD8.sup.+CD39.sup.+CD103.sup.+ T cells. In additional embodiments, methods are disclosed for determining if a subject with a tumor will respond to a checkpoint inhibitor. The methods include detecting the presence of CD8.sup.+CD39.sup.+CD103.sup.+ T cells in a biological sample from a subject.

The present invention is directed to a method of treating a hematologic malignancy such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), including hematologic malignancies that are refractive to chemotherapeutic and/or hypomethylating agents. The method concerns administering a CD123×CD3 bispecific binding molecule to a patient in an amount effective to stimulate the killing of cells of said hematologic malignancy in said patient. The present invention is particularly directed to the embodiment of such method in which a cellular sample (Z from the patient prior to such administration evidences an expression of one or more target genes that is increased relative to a baseline level of expression of such genes, for example, a baseline level of expression of such genes in a reference population of individuals who are suffering from the hematologic malignancy, or with respect to the level of expression of a reference gene.

Disclosed are subpopulations of mammalian stem cell- or mammalian progenitor cell-derived cardiomyocytes. The subpopulations of cardiomyocytes contain a portion of a population of mammalian stem cell- or mammalian progenitor cell-derived cardiomyocytes. The subpopulations of cardiomyocytes can be CD36.sup.+ subpopulations or CD36.sup.− subpopulations. Disclosed are methods of isolating and of using the subpopulations of cardiomyocytes, particularly in cardiac disease modeling, drug screening, cardiotoxicity testing, and cardiac regeneration/repair.

Disclosed herein are methods of detecting the presence or absence of exosomes, the method comprising detecting an exosomal biomarker in a sample obtained from a subject. Also disclosed herein is a system and a biosensor, each for detecting an exosomal biomarker as disclosed herein.

Methods for identifying cancer patients amenable to anti-cancer immunotherapy are provided along with methods of monitoring cancer therapy. Also provided are methods of treating cancer patients amenable to anti-cancer immunotherapy. The methods involve determining the level of CD127 <low> PD-1 <low> T cells. The patients are treated with an immune checkpoint inhibitor, such as an anti-CTLA-4 antibody, e.g. ipilimumab.

The present invention provides an in vitro method for the prognosis of disease progression in a patient that suffers from or is at risk of developing a solid tumor, said method comprising determining, in one or more samples from said patient, at least one of intratumoral infiltration by macrophages, and/or proximity of lymphocytes to tumor cells, and/or proximity of macrophages to tumor cells, and/or presence or absence of one or more nearby tertiary lymphoid structures (TLS), and an anti-angiogenic drug, optionally combined with an immune checkpoint inhibitor, for use in the treatment of such patient.

Provided are antibodies that target the cellular efflux pump ABCG2. Also provided are pharmaceutical compositions, nucleic acids, recombinant expression vectors, cells, and kits that include or encode such antibodies. Methods of using the antibodies for detecting presence or absence of ABCG2 expression in cells, e.g., tumor cells, level of ABCG2 expression, and/or inhibiting ABCG2 function are also disclosed. In addition, multi-specific antibodies that bind to ABCG2 and a polypeptide expressed on surface of a cancer cell are provided. The polypeptide may be the efflux pump MDR1 or a cancer-associated antigen. Also provided are methods for treating a subject for a cancer that include administering to the subject an anti-ABCG2 antibody as disclosed herein or a multi-specific antibody that targets both ABCG2 and a cancer-associated antigen or MDR1.

Provided are an anti-B7-H3 antibody and preparation thereof and a use thereof. Further provided is a drug conjugate and recombinant protein containing the antibody. The antibody of the present invention can be effectively endocytosed by cells, and an antibody-conjugated drug prepared by using the antibody of the present invention shows a tumor inhibition effect.

Provided is an antibody for treating a cancer, more specifically, an anti-CD43 antibody binding to an extracellular domain of CD43, compositions for treating a cancer or inhibiting a cancer stem cell comprising the antibody as an active ingredient, and methods for screening an agent of inhibiting a cancer stem cell.